Is SS-31 Right for You? An Evidence-Based Breakdown

SS-31 at a glance:

• Drug class: Metabolic / longevity research peptide
• Route: subcutaneous injection in research
• Typical frequency: no established human regimen
• Half-life: typically short systemically

Let's cut through the marketing on SS-31 and look at what the data actually say. These peptides target mitochondrial function, AMPK signaling, or other metabolic pathways implicated in aging and metabolic disease, and the result for users is: improvements in insulin sensitivity, exercise capacity, or markers of cellular aging in animal models.

What is SS-31?

These peptides target mitochondrial function, AMPK signaling, or other metabolic pathways implicated in aging and metabolic disease. Most evidence is preclinical.

There is no single FDA-licensed manufacturer of SS-31 for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. SS-31 is not currently approved by the FDA for general human use. Available evidence comes from animal and cell-culture studies. We do not endorse self-administration of unapproved compounds.

The drug class metabolic / longevity research peptide works by targeting specific receptor pathways. Here's how that breaks down.

How SS-31 Works in the Body

These peptides target mitochondrial function, AMPK signaling, or other metabolic pathways implicated in aging and metabolic disease. Most evidence is preclinical. The receptor target — compound-specific — drives the downstream effects users care about: improvements in insulin sensitivity, exercise capacity, or markers of cellular aging in animal models.

The pharmacokinetics matter for daily use. SS-31 has a half-life of typically short systemically, which determines how often it is dosed. The standard route of administration is subcutaneous injection in research, and the typical schedule is no established human regimen.

For more detail on the underlying biology, see our breakdown of how SS-31 works.

Who Uses SS-31?

SS-31 is most relevant for people whose situation maps to its approved indications: none currently approved.

People who should avoid SS-31 include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of SS-31 include:

• limited human data

Serious risks — uncommon but worth knowing — include:

• unknown long-term effects

We have a more detailed breakdown in our SS-31 side-effects guide.

SS-31 vs Alternatives

Evidence-based metabolic therapies include metformin, GLP-1 agonists, and lifestyle interventions. If you are weighing SS-31 against another option, our comparison pages include SS-31 Side Effects: 7 Things to Watch For (and How to Manage Them), NAD+ 101: A Plain-English Guide for 2026, NAD+ Side Effects Decoded: What's Normal vs. What Isn't.

Bottom Line

If you're considering SS-31, the most useful next step is usually a conversation with a clinician who knows the full landscape of options — not just the one they prescribe most often. Evidence remains preliminary; we recommend caution and clinician oversight. If you are considering SS-31, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• SS-31 Side Effects: 7 Things to Watch For (and How to Manage Them)
• NAD+ 101: A Plain-English Guide for 2026
• NAD+ Side Effects Decoded: What's Normal vs. What Isn't
• What Results Should You Expect from NAD+? A Practical Guide
• The Real NAD+ Price Tag in 2026 — With and Without Insurance
• NAD+ Cycle Guide: Published Research vs. Online Protocols

Sources

• Birk AV et al. The Mitochondrial-Targeted Peptide SS-31 Selectively Improves Mitochondrial Function. JASN 2013;24:1250.
• Lee C et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015;21:443.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.